Andere Sprachen Zydus Lifesciences Limited

Aktien

A141X0

INE010B01027

ZYDUSLIFE

Markt geschlossen - NSE India S.E. Andere Börsenplätze 13:51:20 23.04.2024			% 5 Tage	% 1. Jan.
959,4 ^INR	-0,03 %		+1,55 %	+39,21 %

23.04.	Zydus Lifesciences Limited gibt bekannt, dass der Antrag auf ein neues Arzneimittel von Zydus' innovativem Medikament Desidustat Tablets von China Medical System Holdings Limited in China angenommen wurde	CI
22.04.	Zydus Lifesciences Limited bringt Mirabegron-Tabletten mit verlängerter Wirkstofffreisetzung in den USA auf den Markt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

China Medical System's Anti-Anaemia NDA Accepted in China	23.04.
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	23.04.
Zydus Lifesciences Limited Announces New Drug Application of Zydus' Innovative Drug Desidustat Tablets by China Medical System Holdings Limited Accepted in China	23.04.
Zydus launches Mirabegron Extended-Release Tablets in the US	22.04.
Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S	22.04.
Zydus Arm Get UK Drug Regulator's Marketing Approval for Nulibry as MoCD Type A Treatment	22.04.
Zydus Lifesciences Launches Generic Drug for Overactive Bladder in US	22.04.
Zydus Receives Approval from WHO International Non-Proprietary Names for Usnoflast as Recommended Name for ZYIL1	01.04.
Zydus Gets Four Observations from US FDA for Oncology Injectable Plant	28.03.
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Letermovir Tablets, 240 Mg and 480 Mg	23.03.
Zydus Lifesciences Gets US FDA's Final Nod for Finasteride and Tadalafil Capsules	18.03.
Zydus Lifesciences Limited Receives Final Approval from USFDA and 180 Days CGT Exclusivity for Finasteride and Tadalafil Cap Capsules	16.03.
Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.	15.03.
Zydus Lifesciences Gets US FDA Final Nod for Chlorpromazine Hydrochloride Injection; Shares Jump 3%	14.03.
Zydus Receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials	14.03.
Zydus Receives Tentative Approval from the USFDA for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial	14.03.
Zydus Lifesciences Launches Generic Cancer Drug Ibyra in India	13.03.
Zydus Lifesciences Limited Launches IBYRA, the Generic Version of Olaparib	13.03.
Zydus Lifesciences Gets US FDA's EIR for Ahmedabad, India Unit's Inspection	11.03.
Zydus Lifesciences Limited's Equity Buyback announced on February 9, 2024, has closed with 5,970,149 shares, representing 0.59% for INR 6,000 million.	06.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Zydus Lifesciences Limited

Aktien

A141X0

INE010B01027

ZYDUSLIFE

Andere Sprachen

Filter